The different predictive values of carbonic anhydrases in HER2-enriched and Basal-like breast cancer exemplify the heterogeneity of breast cancer and the need for personalized treatment decisions to improve therapeutic responses and lower the risk of harm. This evidence concerns the gene ERBB2 and breast cancer.